| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Dec'16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | |||||||||||||
- | 37,752 | - | 12,926 | - | 234 | 0 | 5,565 | 5,067 | 3,677 | 3,650 | 0 | 0 | 0 |
Sales related party | |||||||||||||
- | 55 | - | -1,199 | - | 204 | 459 | 2,607 | 1,771 | 1,985 | 1,731 | 0 | 0 | 0 |
Total gross sales | |||||||||||||
39,759 | 37,808 | 28,079 | 11,688 | 5,105 | 439 | 459 | 8,172 | 6,839 | 5,662 | 5,381 | 0 | 0 | 0 |
Allowances | |||||||||||||
-2,662 | -4,474 | -4,427 | -4,050 | -2,313 | -202 | 0 | 0 | 0 | 0 | - | 0 | - | - |
Net sales | |||||||||||||
- | 33,278 | - | 8,875 | - | 32 | 0 | 0 | 0 | 0 | - | 0 | - | - |
Net sales related party | |||||||||||||
- | 0 | - | 332 | - | 0 | - | 0 | 0 | 0 | - | 0 | - | - |
Allowances | |||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 |
Net Sales | |||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 |
Net sales related party | |||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 |
Total net sales | |||||||||||||
37,096 | 33,334 | 23,651 | 7,638 | 2,792 | 237 | 459 | 8,046 | 6,635 | 4,962 | 4,474 | 0 | 0 | 0 |
Costs of sales | |||||||||||||
13,489 | 12,671 | 9,136 | 3,284 | 1,432 | 41 | 104 | 2,391 | 1,546 | 1,420 | 1,355 | 0 | 0 | 0 |
Gross profit | |||||||||||||
23,607 | 20,662 | 14,514 | 4,353 | 1,360 | 195 | 355 | 5,655 | 5,089 | 3,542 | 3,119 | 0 | 0 | 0 |
Operating expenses excluding impairment losses | |||||||||||||
- | - | - | 0 | - | - | - | 0 | - | - | - | - | - | - |
Impairment of intangible assets | |||||||||||||
- | - | - | 0 | - | - | - | 0 | - | - | - | - | - | - |
Operating expenses | |||||||||||||
46,998 | 40,480 | 29,311 | 18,549 | 6,668 | 1,856 | 2,152 | 4,911 | 4,300 | 4,446 | 3,358 | 0 | 0 | 0 |
Debt conversion expense | |||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 0 | - | - |
Other than temporary impairment on marketable securities | |||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 0 | - | - |
Gain (loss) on disposal of property and equipment | |||||||||||||
- | - | - | 0 | - | - | - | 0 | 0 | 0 | - | 0 | 0 | 0 |
Interest income (expense) | |||||||||||||
- | - | - | -76 | - | - | - | 265 | 494 | 633 | 500 | 0 | 0 | 0 |
Income (loss) from operations | |||||||||||||
-23,390 | -19,817 | -14,796 | -36,156 | -5,238 | -1,590 | -1,797 | 673 | -132 | -1,963 | -1,361 | 0 | 0 | 0 |
Unrealized loss on marketable securities | |||||||||||||
- | - | - | - | - | - | - | - | - | 0 | - | - | - | - |
Realized and unrealized gain (loss) on marketable securities | |||||||||||||
0 | 0 | - | 0 | 0 | 0 | - | 0 | 0 | 0 | - | - | - | - |
Impairment on investment other securities | |||||||||||||
0 | - | - | - | 0 | - | - | - | - | - | - | - | - | - |
Impairment accounts receivable other | |||||||||||||
0 | - | - | - | 0 | - | - | - | - | - | - | - | - | - |
(Increase) decrease on contingent liability | |||||||||||||
-36,612 | 15,563 | 32,461 | 52,461 | 0 | 0 | - | 0 | 0 | - | - | - | - | - |
Interest income | |||||||||||||
0 | 0 | - | - | 0 | 0 | - | - | - | - | - | - | - | - |
Income (loss) before provision for income taxes | |||||||||||||
0 | 0 | - | - | 0 | 0 | - | - | - | - | - | - | - | - |
Benefit for income taxes | |||||||||||||
-3,391 | -4,466 | -2,359 | -2,302 | -1,152 | -100 | 0 | -11 | -109 | -10 | 25 | 0 | 0 | 0 |
Net income (loss) from continuing operations | |||||||||||||
15,196 | -31,537 | -45,429 | -43,848 | -34,960 | -1,489 | -1,797 | 743 | 788 | -904 | -239 | 0 | 0 | 0 |
Net loss from discontinued operations, net of tax (Note 15) | |||||||||||||
0 | 0 | - | - | 0 | 0 | - | - | - | - | - | - | - | - |
Net income (loss) | |||||||||||||
10,495 | -36,238 | -51,357 | -64,122 | -34,354 | -861 | 62 | 684 | -22 | -1,953 | -1,386 | 0 | 0 | 0 |
Net loss attributable to non-controlling interest | |||||||||||||
0 | 0 | - | - | 0 | 0 | - | - | - | - | - | - | - | - |
Preferred dividends | |||||||||||||
0 | 0 | - | - | 0 | 0 | - | - | - | - | - | - | - | - |
Net loss attributable to non-controlling interest | |||||||||||||
- | - | - | 2,582 | - | - | - | -386 | 41 | 547 | 352 | 0 | 0 | 0 |
Net income (loss) attributable to cbdMD, Inc. common shareholders | |||||||||||||
11,120 | -35,455 | -50,428 | -62,490 | -34,585 | -1,389 | -412 | 139 | -277 | -2,237 | -1,738 | 0 | 0 | 0 |
Net income (loss) per share: | |||||||||||||
Basic earnings per share | |||||||||||||
0.41 | 0.46 | 1.71 | -1.19 | -3.13 | -0.21 | - | 0.03 | 0.17 | - | - | -0.04 | -0.13 | - |
Diluted earnings per share | |||||||||||||
0.40 | 0.45 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.03 | 0.17 | - | - | 0.00 | -0.13 | - |
Weighted average number of shares - basic | |||||||||||||
36,503 | 27,720 | 28,141 | 23,193 | 10,160 | 10,052 | - | 8,075 | 8,025 | - | - | 4,686 | 4,217 | - |
Weighted average number of shares - diluted | |||||||||||||
37,336 | 28,553 | 51,335 | 0 | 10,160 | 10,052 | - | 8,092 | 8,040 | - | - | 0 | 0 | - |
Loss per share, basic and diluted | |||||||||||||
- | - | - | - | - | - | - | - | - | -0.16 | - | - | - | -0.18 |
Weighted average number of shares outstanding | |||||||||||||
- | - | - | - | - | - | - | - | - | 6,911 | - | - | - | 3,485 |